Maintenance therapy for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have nasopharyngeal cancer that has spread to distant parts of the body (stage IV) or has come back and cannot be treated with local therapy
- Your disease has not gotten worse after 4 to 6 cycles of your first chemotherapy combined with immunotherapy (you have stable disease or still have EBV DNA in your blood)
- You are in good enough health to perform daily activities (ECOG score 0 or 1)
- You have adequate blood cell counts and liver and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new treatment for nasopharyngeal cancer that adds an immune-boosting drug (toripalimab) before and after radiation therapy, while skipping radiation to the neck lymph nodes. It aims to see if this approach is effective and reduces side effects.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.